tobramycin (nebcin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, it is effective against gram-negative bacteria, especially the pseudomonas species. Tobramycin is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.   NCATS

Chemistry

  • SMILES: NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O.NC[C@H]4O[C@H](O[C@@H]5[C@@H](N)C[C@@H](N)[C@H](O[C@H]6O[C@H](CO)[C@@H](O)[C@H](N)[C@H]6O)[C@H]5O)[C@H](N)C[C@@H]4O.OS(=O)(=O)O.OS(=O)(=O)O.OS(=O)(=O)O.OS(=O)(=O)O.OS(=O)(=O)O
  • InChIKey: NZKFUBQRAWPZJP-BXKLGIMVSA-N
  • Mol. Mass: 1425.44
  • ALogP: -6.3
  • ChEMBL Molecules:
    tobramycin sulfate  
    tobramycin sulfate  
    tobramycin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1980 - $1795.0300

Australia

$3.0857 - $20.5989
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( tobramycin (nebcin), dexamethasone - other name: tobradex st )
|
( fluorometholone (fml), tobramycin (nebcin) )
|
( tobramycin (nebcin), loteprednol (lotemax) )

Alternative names

3'-deoxykanamycin b | 47663 | aktob | bethkis | bramitob | dexamethasone mixture with tobramycin | nebcin | nebicin | nebramycin | nebramycin 6 | nebramycin factir 6 | nebramycin factor 6 | nebramycin-faktor 6 | nebramycin vi | nebris | o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribohexopyranosyl-(1-4))-2-deoxy-d-streptamine | obramycin | tobi | tobi podhaler | tobracin | tobracin (tn) | tobradex | tobradex st | tobradistin | tobralex | tobramaxin | tobramicin | tobramicina | tobramycetin | tobramycin | tobramycine | tobramycin sulfate | tobramycin sulfate (pharmacy bulk) | tobramycinum | tobravisc | tobrex | tobrex (tn) | tymbrineb | vantobra

Organizations (161)

Research & Development (131)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (34)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (54)

Approved Indications (6)


 

Conjunctivitis, Allergic

Cystic Fibrosis

Eye Infections, Bacterial (approved 1980)

Infections

Inflammation

Otitis Externa

Experimental Indications - Clinical Trial Phases 1-4 (51)


 

Anti-Bacterial Agents (Phase 4)

Arthroplasty, Replacement, Knee (Phase 4)

Bacterial Infections (Phase 3)

Blepharitis (Phase 4)

Bronchiectasis (Phase 4)

Bronchopulmonary Dysplasia (Phase 1)

Burkholderia Infections (Phase 1)

Burns (Phase 1/Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cataract (Phase 4)

Chalazion (Phase 4)

Colorectal Neoplasms (Phase 4)

Conjunctivitis (Phase 4)

Conjunctivitis, Bacterial (Phase 3)

Critical Illness (Phase 3)

Cystic Fibrosis ()

Diabetic Foot (Early Phase 1)

Dry Eye Syndromes (Phase 1)

Exfoliation Syndrome (Phase 4)

Eye Infections (Phase 3)

Fever (Phase 4)

Fractures, Bone (Phase 4)

Fractures, Open (Phase 4)

General Surgery (Phase 3)

Glaucoma, Open-Angle (Phase 4)

Healthy Volunteers (Phase 1)

Hordeolum (Phase 4)

Infections ()

Inflammation ()

Keratitis (Phase 3)

Kidney Failure, Chronic (Phase 1)

Knee Injuries (Phase 4)

Lung Diseases (Phase 3)

Meibomian Gland Dysfunction (Phase 4)

Neoplasms (Phase 4)

Neutropenia (Phase 4)

Pharmacological and Toxicological Phenomena (Phase 4)

Pneumonia (Phase 3)

Pneumonia, Bacterial (Phase 2)

Pneumonia, Ventilator-Associated (Phase 4)

Postoperative Complications (Phase 3)

Prosthesis-Related Infections (Phase 2)

Pseudomonas aeruginosa (Phase 3)

Pseudomonas Infections (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Renal Dialysis (Phase 1)

Sepsis (Phase 3)

Shock, Septic (Phase 3)

Sinusitis (Phase 3)

Surgical Wound Infection (Phase 4)

Wound Infection (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 114
  • # of Trial Organizations: 131

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue